Parenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Moran, Corey S ^a   Seto, Sai Wang ^b   Krishna, Smriti M ^a   Sharma, Surabhi ^a   Jose, Roby J ^a   Biros, Erik ^a   Wang, Yutang ^c   Morton, Susan K ^a   Golledge, Jonathan ^a,d  

^a JAMES COOK UNIVERSITY   (Australia)

^b WESTERN SYDNEY UNIVERSITY   (Australia)

^c UNIVERSITY OF BALLARAT   (Australia)

^d TOWNSVILLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; GELATINASE A; PROTEINASE ACTIVATED RECEPTOR 2; SMAD2 PROTEIN; SMAD3 PROTEIN; THROMBIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; AORTIC ANEURYSM; APOLIPOPROTEIN E KNOCKOUT MOUSE; ATHEROSCLEROSIS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MOUSE; PARENTERAL DRUG ADMINISTRATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTITHROMBINS; AORTIC ANEURYSM; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FACTOR XA INHIBITORS; GENE EXPRESSION REGULATION; INFUSIONS, PARENTERAL; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, KNOCKOUT, APOE; RECEPTOR, PAR-2; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; THROMBIN;

EID: 85013374214     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43079     Document Type: Article

References (48)

1. Golledge, J. & Norman, P. E. Pathophysiology of abdominal aortic aneurysm relevant to improvements in patients' management. Curr. Opin. Cardiol. 24, 532-538 (2009).
2. Golledge, J., Muller, R., Clancy, P., McCann, M. & Norman, P. E. Evaluation of the diagnostic and prognostic value of plasma D-dimer for abdominal aortic aneurysm. Eur. Heart J. 32, 354-364 (2011).
3. Busch, G. et al. Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 25, 461-466 (2005).
4. Demetz, G. & Ott, I. The Interface between Inflammation and Coagulation in Cardiovascular Disease. Int. J. Inflam. 2012, 860301 (2012).
5. Golledge, J., Wolanski, P., Parr, A. & Buttner, P. Measurement and determinants of infrarenal aortic thrombus volume. Eur. Radiol. 18, 1987-1994 (2008).
6. Parr, A. et al. Thrombus volume is associated with cardiovascular events and aneurysm growth in patients who have abdominal aortic aneurysms. J. Vasc. Surg. 53, 28-35 (2011).
7. Houard, X., Ollivier, V., Louedec, L., Michel, J. B. & Back, M. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B-4 as a major chemotactic factor released from the intraluminal thrombus. Faseb Journal 23, 1376-1383 (2009).
8. Touat, Z. et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Amer. J. Pathol. 168, 1022-1030 (2006).
9. Folkesson, M., Silveira, A., Eriksson, P. & Swedenborg, J. Protease activity in the multi-layered intra-luminal thrombus of abdominal aortic aneurysms. Atherosclerosis 218, 294-299 (2011).
10. Bauer, K. A. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J. Thromb. Haemost. 9 Suppl 1, 12-19 (2011).
11. Bohm, A. et al. Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells. Cardiovasc. Res. 99, 505-513 (2013).
12. Borissoff, J. I. et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 122, 821-830 (2010).
13. Borissoff, J. I. et al. Genetic and pharmacological modifications of thrombin formation in apolipoprotein E-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS One 8, e55784 (2013).
14. Preusch, M. R. et al. Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice. Drug Des. Devel. Ther. 9, 5203-5211 (2015).
15. Lee, I. O., Kratz, M. T., Schirmer, S. H., Baumhakel, M. & Bohm, M. The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. J. Pharmacol. Exp. Ther. 343, 253-257 (2012).
16. Kadoglou, N. P. et al. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice: dabigatran etexilate and atherosclerosis. Cardiovasc. Drugs. Ther. 26, 367-374 (2012).
17. Pingel, S. et al. Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Arch. Med. Sci. 10, 154-160 (2014).
18. Zhou, Q. et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm. 2011, 432080 (2011).
19. Zou, P. et al. Effects of the factor Xa inhibitor, fondaparinux, on the stability of atherosclerotic lesions in apolipoprotein E-deficient mice. Circ J. 79, 2499-2508 (2015).
20. Ma, L. & Dorling, A. The roles of thrombin and protease-activated receptors in inflammation. Semin. Immunopathol. 34, 63-72 (2012).
21. McEachron, T. A., Pawlinski, R., Richards, K. L., Church, F. C. & Mackman, N. Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood 116, 5037-5044 (2010).
22. Mihara, K. et al. Thrombin-mediated direct activation of proteinase-activated receptor-2: another target for thrombin signaling. Mol. Pharmacol. 89, 606-614 (2016).
23. Aman, M., Hirano, M., Kanaide, H. & Hirano, K. Upregulation of proteinase-activated receptor-2 and increased response to trypsin in endothelial cells after exposure to oxidative stress in rat aortas. J. Vasc. Res. 47, 494-506 (2010).
24. Damiano, B. P., D'andrea, M. R., De Garavilla, L., Cheung, W. M. & Andrade-Gordon, P. Increased expression of protease activated receptor-2 (PAR-2) in balloon-injured rat carotid artery. Thromb. Haemost. 81, 808-814 (1999).
25. Fukunaga, R. et al. Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. Am. J. Physiol. Heart Circ. Physiol. 291, H2388-H2395 (2006).
26. Jobi, K. et al. Redox regulation of human protease-activated receptor-2 by activated factor X. Free Radic. Biol. Med. 51, 1758-1764 (2011).
27. Rodrigues Diez, R. et al. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-beta-independent process. PLoS One 5, e14145 (2010).
28. Kazi, M. et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J. Vasc. Surg. 38, 1283-1292 (2003).
29. Kotschy, M. et al. Selected clotting factors in blood of patients with abdominal aortic aneurysms. Kardiol. Pol. 70, 574-579 (2012).
30. Daugherty, A., Manning, M. W. & Cassis, L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 105, 1605-1612 (2000).
31. Saraff, K., Babamusta, F., Cassis, L. A. & Daugherty, A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin-II infused, apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23, 1621-1626 (2003).
32. Shriver, Z. et al. Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc. Natl. Acad. Sci. USA 97, 10365-10370 (2000).
33. Wong, N. N. Fondaparinux: a synthetic selective factor-Xa inhibitor. Heart Dis. 5, 295-302 (2003).
34. Wienen, W., Stassen, J. M., Priepke, H., Ries, U. J. & Hauel, N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb. Haemost. 98, 155-162 (2007).
35. Shimizu, K., Mitchell, R. N. & Libby, P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 26, 987-994 (2006).
36. Wang, Y. et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin IIinfused mice. J. Clin. Invest. 120, 422-432 (2010).
37. Moran, C. S. et al. Everolimus limits aortic aneurysm in the apolipoprotein E-deficient mouse by downregulating C-C chemokine receptor 2 positive monocytes. Arterioscler. Thromb. Vasc. Biol. 33, 814-821 (2013).
38. Krishna, S. M. et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 35, 389-398 (2015).
39. Mclean, K., Schirm, S., Johns, A., Morser, J. & Light, D. R. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834. Thromb. Res. 103, 281-297 (2001).
40. Rana, S., Yang, L., Hassanian, S. M. & Rezaie, A. R. Determinants of the specificity of protease-activated receptors 1 and 2 signaling by factor Xa and thrombin. J. Cell Biochem. 113, 977-984 (2012).
41. Koole, D. et al. Osteoprotegerin is associated with aneurysm diameter and proteolysis in abdominal aortic aneurysm disease. Arterioscler. Thromb. Vasc. Biol. 32, 1497-1504 (2012).
42. López-Candales, A. et al. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am. J. Pathol. 150, 993-1007 (1997).
43. Moran, C. S. et al. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 111, 3119-3125 (2005).
44. Moran, C. S., Jose, R. J., Biros, E. & Golledge, J. Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse. Arterioscler. Thromb. Vasc. Biol. 34, 2609-2616 (2014).
45. Longo, G. M. et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110, 625-632 (2012).
46. Krishna, S. M. et al. Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am. J. Pathol. 181, 706-718 (2012).
47. Seto, S. W., Krishna, S. M., Moran, C. S., Liu, D. & Golledge, J. Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein E deficient mouse model. Clin. Sci. (Lond). 127, 123-134 (2014).
48. Biros, E., Walker, P. J., Nataatmadja, M., West, M. & Golledge, J. Downregulation of transforming growth factor, beta receptor 2 and Notch signaling pathway in human abdominal aortic aneurysm. Atherosclerosis 221, 383-386 (2012).